Abstract
Our intestinal microbiota serve many roles vital to the normal daily function of the human gastrointestinal tract. Many probiotics are derived from our intestinal bacteria, and have been shown to provide clinical benefit in a variety of gastrointestinal conditions. Current evidence indicates that probiotic effects are strain-specific, they do not act through the same mechanisms, and nor are all probiotics indicated for the same health conditions. However, they do share several common features in that they exert anti-inflammatory effects, they employ different strategies to antagonize competing microorganisms, and they induce cytoprotective changes in the host either through enhancement of barrier function, or through the upregulation of cytoprotective host proteins. In this review we focus on a few selected probiotics – a bacterial mixture (VSL), a Gram-negative probiotic (E. coli Nissle 1917), two Gram-positive probiotic bacteria (LGG, L.reuteri), and a yeast probiotic (S. boulardii) – for which sound clinical and mechanistic data is available. Safety of probiotic formulations is also discussed.
Keywords: Probiotics, intestinal microbiota, inflammation, colitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science
Volume: 8 Issue: 3
Author(s): Elaine O. Petrof
Affiliation:
Keywords: Probiotics, intestinal microbiota, inflammation, colitis
Abstract: Our intestinal microbiota serve many roles vital to the normal daily function of the human gastrointestinal tract. Many probiotics are derived from our intestinal bacteria, and have been shown to provide clinical benefit in a variety of gastrointestinal conditions. Current evidence indicates that probiotic effects are strain-specific, they do not act through the same mechanisms, and nor are all probiotics indicated for the same health conditions. However, they do share several common features in that they exert anti-inflammatory effects, they employ different strategies to antagonize competing microorganisms, and they induce cytoprotective changes in the host either through enhancement of barrier function, or through the upregulation of cytoprotective host proteins. In this review we focus on a few selected probiotics – a bacterial mixture (VSL), a Gram-negative probiotic (E. coli Nissle 1917), two Gram-positive probiotic bacteria (LGG, L.reuteri), and a yeast probiotic (S. boulardii) – for which sound clinical and mechanistic data is available. Safety of probiotic formulations is also discussed.
Export Options
About this article
Cite this article as:
Petrof O. Elaine, Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8 (3) . https://dx.doi.org/10.2174/187152309789151977
DOI https://dx.doi.org/10.2174/187152309789151977 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Insight into Tissue Unbound Concentration: Utility in Drug Discovery and Development
Current Drug Metabolism Psychological Stress in Pathogenesis of Essential Hypertension
Current Hypertension Reviews Overcoming Chondroitin Sulphate Proteoglycan Inhibition of Axon Growth in the Injured Brain: Lessons from Chondroitinase ABC
Current Pharmaceutical Design Insights into the Zinc-Dependent Deacetylase LpxC: Biochemical Properties and Inhibitor Design
Current Topics in Medicinal Chemistry Clinical, Molecular, and Genetic Characteristics of PAPA Syndrome: A Review
Current Genomics Tumor Necrosis Factor Blockade for Treatment of Inflammatory Bowel Disease: Efficacy and Safety
Current Molecular Pharmacology Etoposide, Topoisomerase II and Cancer
Current Medicinal Chemistry - Anti-Cancer Agents From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery
Current Pharmaceutical Design Correlation between Potassium Channel Expression and Sensitivity to Drug-induced Cell Death in Tumor Cell Lines
Current Pharmaceutical Design The Proteolytic Activation of Angiogenic and Lymphangiogenic Growth Factors in Cancer – Its Potential Relevance for Therapeutics and Diagnostics
Current Medicinal Chemistry Review in Pharmacokinetic Models on Corticosteroids
Mini-Reviews in Medicinal Chemistry Coagulation and Cancer Therapy: The Potential of Natural Compounds
Current Genomics Subject Index to Volume 3
Current Drug Targets - CNS & Neurological Disorders The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection
Current Rheumatology Reviews Purinergic Receptors and Pain
Current Pharmaceutical Design SS31, a Small Molecule Antioxidant Peptide, Attenuates β-Amyloid Elevation, Mitochondrial/Synaptic Deterioration and Cognitive Deficit in SAMP8 Mice
Current Alzheimer Research Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-κB) – a Friend, a Foe, or a Bystander - in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Effect of Simvastatin on Inflammatory Cytokines Balance in Air Pouch Granuloma Model
Inflammation & Allergy - Drug Targets (Discontinued) Effect of Direct-Acting Antiviral Drugs on Erectile Functions among Hepatitis C Patients: A Prospective Interventional Study
Endocrine, Metabolic & Immune Disorders - Drug Targets